SAB Biotherapeutics, Inc.
SABS· Nasdaq
Released Mar 28, 2025, after the close
10-K filed Mar 31, 2025, 90 days after period end · 0000950170-25-046994
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $114.70K | $305.01K | $2.16M | $11.06M |
| Net Income | -$11.39M | -$22.86M |
SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR
| -$7.87M |
| -$11.55M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.